HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences

The ASX healthcare and life sciences sector remains a powerhouse of innovation, delivering critical clinical milestones and scalable commercial technologies to the global stage. As the demand for innovative therapies and advanced medical devices heightens, Australian biotechs and medtechs continue to offer investors opportunities driven by world-class R&D.

To spotlight some of the companies driving this momentum, HealthInvest returns for 2026.

Morgans, IR Department, Stockhead, and AusBiotech Investment have partnered to bring together five innovative healthcare companies, offering investors a unique opportunity to discover the latest breakthroughs shaping the future of healthcare and life sciences investment in Australia.

Presenting companies and speakers include:

• Biome Australia Ltd (ASX: BIO) – Blair Vega Norfolk, Founder and Managing Director
• Dimerix Ltd (ASX: DXB)– Dr Nina Webster, CEO and Managing Director
• Micro-X Ltd (ASX:MX1) – Kingsley Hall, CEO
• Racura Oncology Ltd (ASX: RAC) – Dr Daniel Tillett, CEO and Managing Director
• SomnoMed Ltd (ASX:SOM) – Karen Borg, Co-CEO and Executive Director
  
  

Biome Australia (ASX:BIO)

Founded in 2018 and ASX-listed, Biome Australia develops and commercialises innovative, evidence-based live biotherapeutics and complementary medicines designed to prevent disease and improve health outcomes. Partnering with world-leading microbiome researchers and global experts in strain identification, Biome is advancing next-generation probiotic science targeting specific clinical conditions. Its flagship range, Activated Probiotics®, comprises 23 targeted biotherapeutics clinically validated through rigorous double-blind trials across cardiometabolic, respiratory, women’s health, digestive, musculoskeletal, mental health, and dermatological indications. In a category historically dominated by multinationals, Biome has carved out a space of its own as Australia’s leading practitioner probiotic brand, with proprietary strain development adding further IP value. Distributed exclusively through healthcare practitioners across Australia, New Zealand, Canada, and the EU, Biome is building from a meaningful base with substantial runway ahead — both domestically and internationally.

Dimerix (ASX:DXB)

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix' lead clinical asset, DMX-200, is in a Phase 3 clinical trial as a treatment for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with limited treatment options.

Micro-X (ASX:MX1)

Micro-X Limited (ASX: MX1) is an ASX-listed technology company developing and commercialising advanced x-ray solutions for health and security markets through its Nano Electronic X-ray (NEX) Technology. Its proprietary cold cathode, carbon nanotube emitter technology reduces size, weight and power demands, enabling more portable and versatile imaging products. The company has vertically integrated operations in Adelaide and a growing technical and commercial US team in Seattle. Their portfolio includes mobile digital radiology systems, airport security technology, a portable brain CT for stroke diagnosis, and a full body CT project for ARPA-H.

Racura Oncology (ASX:RAC)

Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a mission to silence cancer. Its lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that binds to G4-DNA and RNA and able to silence the critical cancer growth regulator, MYC. Backed by a robust patent portfolio, Racura is advancing a proprietary formulation (RC220) of (E,E)-bisantrene in a range of cancer indications including a Phase 3 trial in acute myeloid leukaemia (AML) and two Phase 1 trials targeting solid tumours and lung cancer. Collaborating with top-tier global research institutions, Racura is actively pursuing commercial partnerships to advance (E,E)-bisantrene in the clinic.

SomnoMed (ASX: SOM)

SomnoMed is a global leader in oral appliance therapy for the treatment of obstructive sleep apnea. Founded in 2004, the company develops and manufactures clinically proven medical devices including the SomnoDent range, treating mild-to-moderate OSA in patients across 28 countries. With headquarters in Sydney and offices in Europe and the United States, SomnoMed focuses on patient comfort, therapy effectiveness and full compliance in sleep apnea treatment.

---

Join us at our HealthInvest summit on Wednesday, 3rd June 2026.
Whether you're a professional or retail investor, we invite you to attend HealthInvest for an exclusive look into the innovations actively transforming the healthcare landscape.

If you'd like to be part of this exciting event, click the button below